The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
The company reports revenue growth of 26% and PAT growth of 21% YoY
The group has a total of 320 ANDA approvals
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
Subscribe To Our Newsletter & Stay Updated
